Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9270)
All Articles published online
|
Publishing Process of This Article
|
Jul 21, 2017 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967 [PMID: 28785150 DOI: 10.3748/wjg.v23.i27.4958] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i27/4958.htm |
| Number | Citing Articles |
| 1 |
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019; 8(6): 515 doi: 10.3390/cells8060515
|
| 2 |
Rownaq Fares Al-Sofi, Mie Siewertsen Bergmann, Claus Henrik Nielsen, Vibeke Andersen, Lone Skov, Nikolai Loft. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 2024; 25(11): 5793 doi: 10.3390/ijms25115793
|
| 3 |
Giovanni Clemente Actis, Rinaldo Pellicano, Sharmila Fagoonee, Davide Giuseppe Ribaldone. History of Inflammatory Bowel Diseases. Journal of Clinical Medicine 2019; 8(11): 1970 doi: 10.3390/jcm8111970
|
| 4 |
Ziran Wang, Lingjun Kong, Han Zhang, Fengchun Sun, Zijian Guo, Rui Zhang, Yaling Dou. Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis. Frontiers in Pharmacology 2022; 12 doi: 10.3389/fphar.2021.811719
|
| 5 |
Duaa Ahmed Elhag, Manoj Kumar, Marwa Saadaoui, Anthony K. Akobeng, Fatma Al-Mudahka, Mamoun Elawad, Souhaila Al Khodor. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. International Journal of Molecular Sciences 2022; 23(13): 6966 doi: 10.3390/ijms23136966
|
| 6 |
Debora Curci, Marianna Lucafò, Adriana Cifù, Martina Fabris, Matteo Bramuzzo, Stefano Martelossi, Raffaella Franca, Giuliana Decorti, Gabriele Stocco. Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease. Clinical and Translational Science 2021; 14(6): 2184 doi: 10.1111/cts.13075
|
| 7 |
Khalil Khalaf, Krzysztof Janowicz, Marta Dyszkiewicz-Konwińska, Greg Hutchings, Claudia Dompe, Lisa Moncrieff, Maurycy Jankowski, Marta Machnik, Urszula Oleksiewicz, Ievgeniia Kocherova, Jim Petitte, Paul Mozdziak, Jamil A. Shibli, Dariusz Iżycki, Małgorzata Józkowiak, Hanna Piotrowska-Kempisty, Mariusz T. Skowroński, Paweł Antosik, Bartosz Kempisty. CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials. Genes 2020; 11(8): 921 doi: 10.3390/genes11080921
|
| 8 |
Marjolein Drent, Naomi T. Jessurun, Petal A. Wijnen, Otto Bekers, Aalt Bast. Drug-induced comorbidities in patients with sarcoidosis. Current Opinion in Pulmonary Medicine 2022; 28(5): 468 doi: 10.1097/MCP.0000000000000889
|
| 9 |
Sükran Erik, EsmaNur Bülbül, Çigdem Sevim, SedaEren Keskin, Mehtap Kara. Risk of Tumor Necrosis Factor Alpha Inhibitors Usage and Related Adverse Effects. The Journal of Neurobehavioral Sciences 2023; 10(2): 41 doi: 10.4103/jnbs.jnbs_4_23
|
| 10 |
Lili Hu, Handan Tan, Qingfeng Cao, Gangxiang Yuan, Changwei Huang, Guannan Su, Aize Kijlstra, Peizeng Yang. Weak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese Han. Experimental Eye Research 2020; 196: 108045 doi: 10.1016/j.exer.2020.108045
|
| 11 |
Marijana Miler, Nora Nikolac Gabaj, Ivana Ćelap, Simeon Grazio, Vedran Tomašić, Alen Bišćanin, Joško Mitrović, Lovorka Đerek, Jadranka Morović-Vergles, Nada Vrkić, Mario Štefanović. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy. Rheumatology International 2021; 41(12): 2195 doi: 10.1007/s00296-021-05016-w
|
| 12 |
Liliana Lykowska-Szuber, Michal Walczak, Agnieszka Dobrowolska, Marzena Skrzypczak-Zielinska. Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients. European Journal of Gastroenterology & Hepatology 2023; 35(10): 1088 doi: 10.1097/MEG.0000000000002618
|
| 13 |
Maria Markelova, Anastasia Senina, Dilyara Khusnutdinova, Maria Siniagina, Elena Kupriyanova, Gulnaz Shakirova, Alfiya Odintsova, Rustam Abdulkhakov, Irina Kolesnikova, Olga Shagaleeva, Svetlana Lyamina, Sayar Abdulkhakov, Natalia Zakharzhevskaya, Tatiana Grigoryeva. Association between Taxonomic Composition of Gut Microbiota and Host Single Nucleotide Polymorphisms in Crohn’s Disease Patients from Russia. International Journal of Molecular Sciences 2023; 24(9): 7998 doi: 10.3390/ijms24097998
|
| 14 |
Mohamed H. Babiker-Mohamed, Sambhawana Bhandari, Prabha Ranganathan. Pharmacogenetics of therapies in rheumatoid arthritis: An update. Best Practice & Research Clinical Rheumatology 2024; : 101974 doi: 10.1016/j.berh.2024.101974
|
| 15 |
Charalabos Antonatos, Eleana F Stavrou, Evangelos Evangelou, Yiannis Vasilopoulos. Exploring Pharmacogenetic Variants for Predicting Response to Anti-TNF Therapy in Autoimmune Diseases: a Meta-Analysis. Pharmacogenomics 2021; 22(7): 435 doi: 10.2217/pgs-2021-0019
|
| 16 |
Marco Gasparetto, Caterina Strisciuglio, Amit Assa, Kostantinos Gerasimidis, Federica Giachero, Jan Novak, Philip Robinson, Bálint Tél, Matthias Zilbauer, Andreas Jenke. Making Research Flourish Through ESPGHAN. Journal of Pediatric Gastroenterology and Nutrition 2022; 74(2): 301 doi: 10.1097/MPG.0000000000003250
|
| 17 |
Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin, Edoardo Savarino, Fabiana Zingone, Francesca Ometto, Marta Favero, Andrea Doria, Stephan R. Vavricka, Roberta Ramonda. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies. Nature Reviews Rheumatology 2023; 19(8): 503 doi: 10.1038/s41584-023-00984-8
|
| 18 |
Hussein Mahajna, Shomron Ben-Horin. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. Current Opinion in Pharmacology 2020; 55: 132 doi: 10.1016/j.coph.2020.10.011
|
| 19 |
Marianna Lucafò, Raffaella Franca, Davide Selvestrel, Debora Curci, Letizia Pugnetti, Giuliana Decorti, Gabriele Stocco. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(12): 1209 doi: 10.1080/17425255.2018.1551876
|
| 20 |
Sophie Vieujean, Edouard Louis. Precision medicine and drug optimization in adult inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231173331
|
| 21 |
Atsushi Yoshida, Koji Kimura, Toshio Morizane, Fumiaki Ueno. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study. European Journal of Gastroenterology & Hepatology 2022; doi: 10.1097/MEG.0000000000002372
|
| 22 |
Claire Wang, Hannah M. Baer, Daniel R. Gaya, Robert J.B. Nibbs, Simon Milling. Can molecular stratification improve the treatment of inflammatory bowel disease?. Pharmacological Research 2019; 148: 104442 doi: 10.1016/j.phrs.2019.104442
|
| 23 |
Raja Atreya, Markus F. Neurath, Britta Siegmund. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Frontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00517
|
| 24 |
Stephen J. O’Brien, Jacob Hallion, Katharina M. Scheurlen, Casey Fiechter, James Burton, Mason Paas, Miranda Schmidt, Sarah Gardner, Maurice R. Eichenberger, Jianmin Pan, Shesh Rai, Susan Galandiuk. Crohn’s disease–related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis. Journal of Gastrointestinal Surgery 2021; 25(9): 2377 doi: 10.1007/s11605-020-04884-0
|
| 25 |
Rita Lauro, Federica Mannino, Natasha Irrera, Francesco Squadrito, Domenica Altavilla, Giovanni Squadrito, Giovanni Pallio, Alessandra Bitto. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021; 9(12): 1748 doi: 10.3390/biomedicines9121748
|
| 26 |
Stefania Cheli, Diego Savino, Annalisa De Silvestri, Lorenzo Norsa, Naire Sansotta, Francesca Penagini, Dario Dilillo, Roberto Panceri, Dario Cattaneo, Emilio Clementi, Giovanna Zuin. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study. The Pharmacogenomics Journal 2023; 23(5): 112 doi: 10.1038/s41397-023-00304-z
|
| 27 |
Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin. Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD). Česko-slovenská pediatrie 2024; 79(4): 213 doi: 10.55095/CSPediatrie2024/008
|
| 28 |
Mirabella Zhao, Johan Burisch. Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease. Digestive Diseases and Sciences 2019; 64(7): 1759 doi: 10.1007/s10620-019-05648-w
|
| 29 |
Milena Peruhova, Dimitrina Miteva, Maria Kokudeva, Sonya Banova, Tsvetelina Velikova. Cytokine Signatures in Inflamed Mucosa of IBD Patients: State-of-the-Art. Gastroenterology Insights 2024; 15(2): 471 doi: 10.3390/gastroent15020034
|
| 30 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 31 |
Zhen Zeng, Mingshan Jiang, Xi Li, Jing Yuan, Hu Zhang. Precision medicine in inflammatory bowel disease. Precision Clinical Medicine 2023; 6(4) doi: 10.1093/pcmedi/pbad033
|
| 32 |
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad, Souhaila Al Khodor. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. Journal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-05058-1
|
| 33 |
Toer W. Stevens, Mijntje Matheeuwsen, Maria H. Lönnkvist, Claire E. Parker, Manon E. Wildenberg, Krisztina B. Gecse, Geert R. D’Haens. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy. Alimentary Pharmacology & Therapeutics 2018; 48(11-12): 1213 doi: 10.1111/apt.15033
|